Quan Anh Vu insider trades

Open-market stock purchases and sales by Quan Anh Vu, Chief Financial Officer at Monopar Therapeutics, from SEC Form 4 filings since Dec 8, 2021.

Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +54%.

Recent trades

DateStockTradeValue
Sep 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Sep 30, 2026MNPR Monopar TherapeuticsSold (not open market)$14.3K
Sep 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Jun 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Jun 30, 2026MNPR Monopar TherapeuticsSold (not open market)$46.9K
Jun 30, 2026MNPR Monopar TherapeuticsBought (not open market)—
Dec 26, 2025MNPR Monopar TherapeuticsBought$105K
Dec 2, 2025MNPR Monopar TherapeuticsBought (not open market)—
Dec 2, 2025MNPR Monopar TherapeuticsBought (not open market)—

Companies traded

  • MNPR Monopar Therapeutics: 1 buy, last Sep 30, 2026
  • ATNF 180 Life Sciences Corp: 2 buys, last Dec 16, 2021

Get free alerts when Quan Anh Vu files a new trade →